A+ R A-

IWWM-10 Posters: W1 - W39

The following abstracts represent Posters W1-W39 that were presented at IWWM-10 (NYC-2018) Poster Session. "ORAL" signifies a 10-minute oral presentation was given during the poster session.

Session Chairs: Ranjana Advani (USA) and Marvin Stone (USA)

W1: MYD88 p.(L265P) detection on cell-free DNA in plasma and cerebrospinal fluid L. Hiemcke-Jiwa, Netherlands

W2: Treatment of IgM-associated immunoglobulin light chain amyloidosis with Bendamustine-Rituximab R. Manwani, United Kingdom

W3: Mast Cell Density and Its Clinical Relevance in Waldenström's Macroglobulinemia R. Lemal, France

W4: Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia J. Paludo, USA

W5: Depth of Response in Waldenstrom Macroglobulinemia J. Paludo, USA

W6: Efficacy of zanubrutinib in the treatment of Bing Neel Syndrome J. Wong, Australia

W7: Updated Analysis of Half-Dose CHOP Combined with Rituximab as Primary Therapy for Symptomatic Waldenström Macroglobulinemia: Single Institutional Experience in Japan N. Sekiguchi, Japan

W8: Serum Transforming Growth Factor-Beta 1 (TGF-BETA 1) Levels predict survival and time to Treatment in Waldenstrom's macroglobulinemia (WM) M.C. Kyrtsonis, Greece

W9: Two Dose Series of High Dose Influenza Vaccine is Associated with Longer Duration of Serologic Immunity in Patients with Waldenstrom's macroglobulinemia and other Plasma Cell Disorders A Branagan, USA

W10: Sequential analysis of TP53 variation using targeted Next Generation Sequencing (NGS) in patients with Waldenström Macroglobulinemia A Christian, United Kingdom

W11: A single centre case series of patients with Waldenström's Macroglobulinemia and Acquired von Willebrand Syndrome L.F. Gamble, United Kingdom

W12: Digital PCR is highly sensitive method for the detection of MYD88 L265P mutation in bone marrow trephine biopsies of lymphomas with plasmacytic/plasmacytoid differentiation E. Willenbacher, Austria

W13: Detection of MYD88 L265P mutation by digital PCR in peripheral blood samples from IgM monoclonal gammopathy patients E. Abella, Spain

W14: Natural history of IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia N. Tovar, Spain

W15: The EBMT/ECWM/IWMF consensus project on the role of autologous and allogeneic stem cell transplantation in Waldenstrom's Macroglobulinemia C. Kyriakou, United Kingdom

W16: Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenstrom Macroglobulinemia reveals different patterns of clonal evolution D. Talaulikar, Australia

W17: Philadelphia chromosome positive acute lymphoblastic leukemia arising in Waldenstrom's macroglobulinemia J. Kothari, United Kingdom

W18: WhiMSICAL (Waldenstrom's Macroglobulinemia Study Involving Cart-wheeL): A Global WM Registry for the Patient's Voice I Tohidi-Esfahani, Australia

W19: Comprehensive metabolomic analysis identifies deregulated metabolic pathways associated with immune dysfunction in Waldenstrom Macroglobulinemia S. Jalali, USA

W20: Health-related quality of life in Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS): a single-center experience A Frustaci, Italy

W21: Dual PAK4-NAMPT Inhibition Impacts Growth and Survival and Increases Sensitivity to DNA-Damaging Agents in Waldenstrom Macroglobulinemia M Fulciniti, USA

W22: Bleeding disorders associated with IgM paraproteinemia and response to treatment: Illustrative Case series from Waldenstrom Macroglobulinemia United Kingdom (WMUK) Forum R. Krishna, United Kingdom

W23 ORAL: Incidence and inheritance of hyperphosphorylated paratag-7 in patients with Waldenstrom's Macroglobulinemia from Sweden L. Brandefors, Sweden

W24: Real World Experience of Bendamustine in Waldenstrom's Macroglobulinaemia (WM): efficacy tempered by toxicity H. Richards, United Kingdom

W25: The Rory Morrison Registry (RMR) for Waldenstrom Macroglobulinemia: A successful doctor-patient collaboration for comprehensive data collection on all-WMer’s J. Bomsztyk, United Kingdom

W26: Novel phenotypically distinct small B cell lymphoma clones may be associated with IgM paraprotein associated peripheral neuropathy L. Chen, United Kingdom

W27: Waldenstrom Macroglobulinaemia: Patient characteristics and outcomes according to MYD88 status in a UK population MD. El-Sharkawi, United Kingdom

W28: IgM Smoldering Multiple Myeloma in a young patient over six years follow-up: case report of an extremely rare hematologic entity A Abbadessa, Italy

W29: Long Term follow-up of Waldenstrom Macroglobulinemia patients’ primary treated with Dexamethasone, Rituximab, and Cyclophosphamide: a single centre experience V. Del Fabro, Italy

W30: Three Cases of IgM-Related AL Amyloidosis Associated to Waldenstrom Macroglobulinemia with MYD88 L265P mutation, Treated with Bortezomib Based Regimens: A single center experience M. Riva, Italy

W31: Waldenstrom's Macroglobulinemia in Young Patients: Disease Characteristics and Clinical Outcome in Patients aged less than 55 years I Defrancesco, Italy

W32 ORAL: Assessment of molecular response using real-time quantitative polymerase chain reaction (RT-qPCR) for MYD88 (L265P) in patients with Waldenström's macroglobulinemia treated with immuno-chemotherapy I Defrancesco, Italy

W33: Progression risk-based classification of Asymptomatic Waldenström Macroglobulinemia: a large single-center study M. Bustoros, USA

W34: Discriminating between Waldenström's Macroglobulinemia and Marginal zone lymphoma using clinicopathological and molecular features K. Amaador, Netherlands

W35: Clonality assessment represents a novel biomarker to predict outcomes on ibrutinib therapy for patients with Waldenström macroglobulinemia carrying CXCR4 S338X nonsense mutations J. Gustine, USA

W36: TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinemia J. Gustine, USA

W37: Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenström Macroglobulinemia J. Gustine, USA

W38 ORAL: Real Life Outcome of Lymphoplasmacytic Lymphoma and Splenic Marginal Zone Lymphoma: An Analysis from the NF10 Project, and International, Prospective, Observational Study of the Fondazione Italiana Linfomi L. Arcaini, Italy

W39: BLIMP1 as a pro-survival gene in Waldenström's Macroglobulinemia E. Magnúsdóttir, Iceland

Amsterdam 2016 (IWWM-9)

Amsterdam 2016 Organizers

  • MJ Kersten MD, Ph.D (U. Amsterdam)
  • Monique Minnema MD, Ph.D (UMC Utrecht)
  • Steven Pals MD, Ph.D (U. Amsterdam)
  • Steven Treon MD, Ph.D (Dana-Farber)
  • Chris Patterson - Secretariat (Dana-Farber)

The Amsterdam 2016 Scientific Committee members:

Stephen Ansell MD, PhD (USA)
Christian Buske MD, PhD (Germany)
Jorge Castillo MD (USA)
Meletios Dimopoulos MD (Greece)
Ramón García-Sanz MD, PhD (Spain)
Marie Jóse Kersten MD, PhD (Netherlands)
Douglas E Joshua AM (Australia)
Véronique Leblond MD (France)
Xavier Leleu MD, PhD (France)
Mary McMaster MD, PhD (USA)
Giampaolo Merlini MD (Italy)
Monique Minnema MD, PhD (Netherlands)
Enrica Morra MD (Italy)
Roger Owen MD, MRCP, FRCPath (UK)
S.T. Pals, MD, PhD (Netherlands)
Linda Pilarski PhD (Canada)
Steven Treon MD PhD (USA)

Click here to download the preliminary program agenda for the 9th International Workshop on WM (IWWM-9).

Registration is closed for this event.

Amsterdam 2016 (IWWM-9) was held at the Renaissance Hotel in Amsterdam.

Renaissance Hotel Amsterdam

Please enjoy this interactive sightseeing map of Amsterdam:

Interactive Map of Amsterdam

New York 2018 (IWWM-10)

New York 2018 Conference Chairs

  • Jorge Castillo, MD (Dana-Farber)
  • Richard Furman, MD (Cornell University)
  • M. Lia Palomba, MD (Memorial Sloan Kettering)
  • Steven Treon, MD, PhD (Dana-Farber)
  • Chris Patterson - Secretariat (Dana-Farber)

The New York 2018 Scientific Committee members:

Ranjana Advani, MD (USA)
Jorge Castillo MD (USA)
Meletios Dimopoulos MD (Greece)
Ramón García-Sanz MD, PhD (Spain)
Zachary Hunter, PhD (USA)
Efstathios Kastritis, MD, PhD (Greece)
Marie Jóse Kersten MD, PhD (Netherlands)
Douglas E Joshua AM (Australia)
Véronique Leblond MD (France)
Giampaolo Merlini MD (Italy)
Roger Owen MD, MRCP, FRCPath (UK)
S.T. Pals, MD, PhD (Netherlands)
Marvin Stone, MD (USA)
Marzia Varretoni, MD (Italy)

Registration for this meeting is now closed.

New York 2018 (IWWM-10) was held at the New York Marriott Downtown in New York City.

New York Marriott Downtown

Click here to download our New York City visitor's guide